Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Investment Securities: 2016-2024

Historic Gains from Investment Securities for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $52.1 million.

  • Collegium Pharmaceutical's Gains from Investment Securities fell 100.12% to -$19,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 87.49%. This contributed to the annual value of $52.1 million for FY2024, which is 115.20% up from last year.
  • As of FY2024, Collegium Pharmaceutical's Gains from Investment Securities stood at $52.1 million, which was up 115.20% from $24.2 million recorded in FY2023.
  • Collegium Pharmaceutical's 5-year Gains from Investment Securities high stood at $52.1 million for FY2024, and its period low was $3.9 million during FY2020.
  • Over the past 3 years, Collegium Pharmaceutical's median Gains from Investment Securities value was $24.2 million (recorded in 2023), while the average stood at $28.9 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Gains from Investment Securities decreased by 2.41% in 2020, and later skyrocketed by 132.74% in 2023.
  • Collegium Pharmaceutical's Gains from Investment Securities (Yearly) stood at $3.9 million in 2020, then soared by 67.23% to $6.5 million in 2021, then surged by 61.09% to $10.4 million in 2022, then surged by 132.74% to $24.2 million in 2023, then skyrocketed by 115.20% to $52.1 million in 2024.